Absence of minimal residual disease (MRD) by reverse transcription polymerase chain reaction (RT-PCR) in CBF beta/MYH11-associated acute myeloid leukemia.

被引：0
|
作者：
Marcucci, G
Caligiuri, MA
Oberkircher, AR
Bloomfield, CD
机构：
[1] OHIO STATE UNIV,DIV HEMATOL ONCOL,COLUMBUS,OH 43210
[2] OHIO STATE UNIV,ARTHUR G JAMES CANC HOSP,DIV HUMAN CANC GENET,COLUMBUS,OH 43210
[3] OHIO STATE UNIV,RES INST,COLUMBUS,OH 43210
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：270 / 270
页数：1
相关论文
共 50 条
  • [1] Detection of minimal residual disease (MRD) by RT-PCR in childhood acute myeloid leukemia (AML).
    Viehmann, S
    Creutzig, U
    Borkhardt, A
    Blütters-Sawatzki, R
    Harbott, J
    BLOOD, 1999, 94 (10) : 215B - 215B
  • [2] Use of the polymerase chain reaction for the detection of CBF beta/MYH11 fusion transcripts in patients with acute myeloid leukemia.
    Schmohl, D
    Dohner, H
    Fischer, K
    Schlenk, R
    Haas, R
    Moos, M
    BLOOD, 1995, 86 (10) : 3101 - 3101
  • [3] Prospective monitoring of minimal residual disease by polymerase chain reaction in patients with acute myeloid leukemia expressing CBF beta/MYH11 fusion transcripts.
    Moos, M
    Schmohl, D
    Botz, D
    Fischer, K
    Schlenk, R
    Dohner, H
    BLOOD, 1997, 90 (10) : 3721 - 3721
  • [4] Bone marrow smears are suitable for the detection of minimal residual disease (MRD) by reverse transcriptase polymerase chain reaction (RT-PCR)
    Schoch, R
    Schafhausen, P
    Haferlach, T
    Jenisch, S
    Kronke, M
    Gassmann, W
    Loffler, H
    BLOOD, 1995, 86 (10) : 3102 - 3102
  • [5] Prospective monitoring of minimal residual disease by polymerase chain reaction in patients with acute myeloid leukemia expressing CBF beta 1MYH11 fusion transcripts.
    Moos, M
    Schmohl, D
    Fischer, K
    Schlenk, R
    Diehl, D
    Haas, R
    Dohner, H
    BLOOD, 1996, 88 (10) : 2237 - 2237
  • [6] Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFβ/MYH11 RT-PCR:: Implications for a monitoring schedule and for treatment decisions
    Laczika, K
    Mitterbauer, G
    Mitterbauer, M
    Knöbl, P
    Schwarzinger, I
    Greinix, HT
    Rabitsch, W
    Fonatsch, C
    Mannhalter, C
    Lechner, K
    Jaeger, U
    LEUKEMIA & LYMPHOMA, 2001, 42 (05) : 923 - 931
  • [7] Monitoring of minimal residual disease in patients with acute myeloid leukemia (AML) and translocation (8;21) or inversion (16) by reverse transcriptase polymerase chain reaction (RT-PCR)
    Schafthausen, P
    Schoch, R
    Haferlach, T
    Nickelsen, M
    Jenisch, S
    Kronke, M
    Gassmann, W
    Loffler, H
    BLOOD, 1995, 86 (10) : 1316 - 1316
  • [8] DETECTION OF MINIMAL RESIDUAL DISEASE (MRD) ON BONE-MARROW SMEARS BY REVERSE-TRANSCRIPTASE POLYMERASE CHAIN-REACTION (RT-PCR)
    HAFERLACH, T
    SCHOCH, R
    SCHATHAUSEN, P
    JENISCH, S
    GASSMANN, W
    KRONKE, M
    LOFFLER, H
    EXPERIMENTAL HEMATOLOGY, 1995, 23 (08) : 762 - 762
  • [9] Comprehensive analysis of CBFβ-MYH11 fusion transcripts in acute myeloid leukemia by RT-PCR analysis
    Kadkol, SS
    Bruno, A
    Dodge, C
    Lindgren, V
    Ravandi, F
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2004, 6 (01): : 22 - 27
  • [10] Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts
    A Guerrasio
    C Pilatrino
    D De Micheli
    D Cilloni
    A Serra
    E Gottardi
    A Parziale
    F Marmont
    D Diverio
    M Divona
    F Lo Coco
    G Saglio
    Leukemia, 2002, 16 : 1176 - 1181
12345